Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial

• DOI: 10.1007/s11255-017-1507-0
• Publication Date: 2017-01-20T11:27:09Z
• Authors: Hong Ren; Xiao Li; Zhao-Hui Ni; Jian-Ying Niu; Bin Cao; Jie Xu; Hong Cheng; Xiao-Wen Tu; Ai-Min Ren; Ying Hu; Chang-Ying Xing; Ying-Hong Liu; Yan-Feng Li; Jun Cen; Rong Zhou; Xu-Dong Xu; Xiao-Hui Qiu; Nan Chen
• Keywords: Regimen; Intravenous therapy; Nephrology

To compare the efficacy and safety of short-course intravenous levofloxacin (LVFX) 750 mg with a conventional intravenous/oral regimen LVFX 500 in patients from China complicated urinary tract infections (cUTIs) acute pyelonephritis (APN). This was prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Patients cUTI APN were randomly assigned to therapy group (intravenous at750 mg/day for 5 days) or (intravenous/oral at 7–14 days). The clinical, laboratory, microbiological results evaluated safety. median dose 3555.4 4874.2 group. Intention-to-treat analysis indicated effectiveness (89.87%, 142/158) non-inferior that (89.31%, 142/159). rates also similar (short-course therapy: 89.55%, 60/67; 86.30%, 63/73; p > 0.05). There no significant differences other parameters, including recurrence rates. incidence adverse effects drug-related (21.95%, 36/164; 18.90%, 31/164) (23.03%, 38/165; 15.76%, 26/165). cUTIs who given had outcomes efficacy, tolerance, described here is more convenient alternative potential implication anti-resistance cost saving.